Articles On Amplia Therapeutics (ASX:ATX)

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis (IPF) patients. This work is being suppo...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis. The results confirmed the company’s prelimi...

Wall Street, European stocks rebound on the dip All three US benchmarks rallied overnight, along with the European sharemarkets as investors bought the dip. The Dow Jones rose 1.62%, S&P 500 by 1.52%, while the Nasdaq rose by 1.57%. The...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat patients with pancreatic cancer. The Melbo...

Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

The Amplia Therapeutics Ltd (ASX: ATX) share price is one of the best performers on the ASX today. This comes after the pharmaceutical company announced positive news in trials to improve pancreatic cancer survival. At one point in intrada...

Summary Amplia Therapeutics has received promising data from its Focal Adhesion Kinase inhibitor in the treatment of cancer. Spectur expects to post a record revenue of approximately AU$1.8 million in Q4. Douugh has formed a strategic...

Biotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data. The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK). FAK is a protein that is over-expressed...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Amplia Therapeutics (ASX:ATX) says it has received new data from its collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research in Sydney.

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr...

After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos...

Small caps have declined for the fourth time in the past five days — but still finished April with their strongest performance in six months. The Small Ordinaries index gained 4.83 per cent in April despite declining 0.96 per cent this week...

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Summary Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH. The positive data from the animal study is anticipated to support the future development and part...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Source: REDPIXEL.PL, Shutterstock Summary Total Brain introduced discrete & continuous HRV functionality to its existing mental health self-monitoring and self-care platform. Electrochemical strips developer Universal Biosensors I...

Amplia Therapeutics (ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase...

Wall Street at record highs again after Fed speech US stocks rose to record highs again after the US Federal Reserve decided to keep rates at near zero until 2023. Fed chairman Jerome Powell said that he expected growth for 2020 to be 6.5 p...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic, the healthcare sector has continued to witness new heights. Penny stocks are grabbing attention from market participants as they are low-pr...

The Amplia Therapeutics Ltd (ASX: ATX) share price is running higher today following the initiation of a multiple-dose study using AM945. During late-morning trade, shares in the Australian pharmaceutical company are up 7% to 29 cents. Amp...

Melbourne-based ASX-listed biotechnology company Amplia Therapeutics (ASX:ATX) will develop a potential new pancreatic cancer therapy discovered by scientists at the Cancer Therapeutics CRC.

Shareholders in Antisense Therapeutics, Amplia Therapeutics and Immutep all had reason to smile this week A trio of capital raisings ... Read More The post ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs appeared fir...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has received clearance from the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a Phase 1 clini...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has announced that it has appointed Dr. Mark Devlin as the company's Chief Scientific Officer. What are the key h...

ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its upcoming Phase 1 clinical trial testing AMP945, the Company’s...

The Amplia Therapeutics Ltd (ASX: ATX) share price is up 16.67% since Tuesday’s open to 14 cents per share, as former Macquarie Group Ltd (ASX: MQG) CEO Allan Moss announced that he had become a substantial holder. What was in the announce...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has successfully completed the Institutional Entitlement Offer component of its fully underwritten, accelerated,...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has received preliminary final results from the preclinical toxicology studies being conducted with its FAK inhib...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has released a new investor presentation which provides an update on the Company’s technology and its near-term a...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

A quick wrap of the key winners and losers on Wednesday, May 20. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potential market-moving announcements during the day. WINNERS: CODE COMPANY PRICE...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received a second orphan drug designation from the US Food and Drug Administration for its focal adhesion kinase inhibitor AMP945. The designation has been awarded for the use of AMP...

A quick wrap of the key winners and losers on Tuesday, May 19. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potential market-moving announcements during the day.   WINNERS: Code Company Price...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has announced that the United States Food and Drug Administration (FDA) has awarded a second Orphan Drug Designat...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received regulatory approval from the US Food and Drug Administration (FDA) for its Focal Adhesion Kinase inhibitor (FAKi) AMP945 – a novel new treatment for pancreatic cancer. The c...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) today announced that the United States Food and Drug Administration (FDA) has awarded Amplia’s Focal Adhesion Kin...